National Cancer Institute CRO Aviano

Cell models to evaluate activity of p53:MDM2 inhibitors

Posted by LUCIA from National Cancer Institute CRO AvianoResponsive · Innovative Products and Technologies · Italy

Summary of the technology

Twist GAIN-of-function and LOSS-of-function cell models were developed and used for preclinical p53:MDM2 inhibitors evaluation, preliminary demonstrating that the expression of Twist hampers their efficacy.
These findings support patient stratification on the basis of twist expression for treatment of a large fraction of sarcomas but also of a fraction of carcinomas. (Piccinin et al., Cancer Cell, 22, 404-415, Sept 11 2012).

National Cancer Institute CRO Aviano

Current development status

3 different cell lines were consistently characterized.

2 more cell lines are producing promising results.

6 different drugs have already been tested including nutlin3a - AMG 232 - RG7112 - SAR405838.

More than 100 cell vitality tests have been performed.

Currently the knowhow related to the technology is secret. The best IPR protection strategy is under evaluation.

Technology Owner

National Cancer Institute CRO Aviano

Research Institute

Additional information (attached documents)

Related keywords

  • Biological Sciences
  • Medicine, Human Health
  • Cytology, Cancerology, Oncology
  • Medical Research
  • Pharmaceutical Products / Drugs
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • In vitro Testing, Trials Technology

About National Cancer Institute CRO Aviano

Research Institute from Italy

National Cancer Institute CRO-Aviano is an Italian public institute funded in 1984 and is committed to pursue excellence in all aspects of clinical oncology and management of health services. CRO is also an excellence in translational and clinical research activity. Our structure performs an average of 378740 patient exams/year, 8295 pts admitted/year (50% are extra-regional) for medium-long term stays and day hospital treatment. Scientific production sets above of 230 scientific papers in journals with Impact Factor (IF), ranking in the set of the 10% most cited papers in their respective scientific field, having a total IF>1000. Clinical trials average 60 per year.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.